CASI Pharmeceuticals

Investor Center

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company employs a global drug-development strategy that leverages our expertise and resources in North America and China. By conducting trials under both North American and Chinese regulatory pathways, the The Company intends to reach clinical efficacy inflection points with drug candidates at greater cost-efficiencies. CASI’s lead compound, ENMD-2076, a selective kinase inhibitor is currently in multiple Phase II studies in triple-negative breast cancer, soft tissue sarcoma, and ovarian clear cell carcinoma in U.S. and Canada, with plans to expand trials into China. Its second compound, 2ME2 (2-methoxyestradiol), has demonstrated promising preclinical results in autoimmune disorders including rheumatoid arthritis and multiple sclerosis, and was previously under clinical investigation for various cancers. CASI intends to continue its evaluation of 2ME2 for further internal development. In addition, the Company is actively pursuing in-licensing opportunities and internal development to enrich its product pipeline.

Investor Downloads

​Corporate Presentation
​Corporate Fact Sheet
China Partnering Presentation
Letter From the CEO

10-K Downloads

2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013

SEC Filings

View all SEC filings, View only Section 16 SEC filings
Please note that the above are links to www.sec.gov, a third-party web site. EntreMed, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the the information contained therein. Further, EntreMed takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.

XBRL Documents

View our Form 10-Q and Form 10-K filings in an interactive data format - the eXtensible Business Reporting Language (XBRL). Learn more about XBRL, or download our filings below:

Q1 2014 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

2013 Form 10-K - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q3 2013 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q2 2013 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q1 2013 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

2012 Form 10-K - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q3 2012 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q2 2012 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

Q1 2012 - View with SEC XBRL Viewer
XBRL Taxonomy Extension Presentation Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Schema Document
XBRL Instance Document

In order to read our interactive data filings, you will need an XBRL viewer such as the viewer provided by the SEC at www.SEC.gov.

Corporate Governance Documents
Code of Ethics
Audit Committee Charter
Compensation Committee Charter

Safe Harbor Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company’s Securities and Exchange Commission filings under “Risk Factors,” including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of ENMD-2076; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

EntreMed leverages best of China and the West and seeks to expand pipeline.

Read Article →

Poster

Phase II Study of Oral ENMD-2076 Administered to Patients (pts) With Advanced Soft Tissue Sarcoma

Download →

Poster

Phase II Study of Oral ENMD-2076 Administered to Patients with Ovarian Clear Cell Carcinoma

Download →